BCAC’s 16th AGM on Tuesday evening went very well. We can’t say the venue was packed – as it was held completely online – but our screens were very busy and the comments section was filled with positive feedback!
Here’s an easy way to get Christmas gifts organised well in advance and to help BCAC at the same time. By clicking here you can buy gift certificates for those friends and family who already have everything they need, but would get a great feeling knowing they are helping women with breast cancer.
NZ breast cancer specialists, assisted by the Breast Cancer Foundation NZ, have just published a new set of consensus guidelines for treating advanced breast cancer (ABC-NZ2). Patient representatives from Metavivors NZ, Sweet Louise and BCAC also contributed to the guidelines.
Christmas is coming! But don’t panic – BCAC’s partnership with The Good Registry can make gift-giving easy this year. By clicking here you can buy gift certificates for those friends and family who already have everything they need, but would get a great feeling knowing they are helping women with breast cancer. The Good Registry is a great volunteer organisation set up by some Wellington women who are passionate about doing good....
BCAC Committee members Fay Sowerby, Libby Burgess and Emma Crowley attended the Breast Cancer inSIGhts conference on 1-3 September 2022 in Auckland. This biennial conference is run by the Breast Cancer Foundation NZ and the Breast Special Interest Group of NZ specialists.
Dr Emma Nolan is a breast cancer scientist who recently moved back to New Zealand after training and working in overseas labs for the last 11 years. During her PhD, Emma helped to discover a potential preventative medication, Denosumab, that could potentially prevent or delay breast cancer arising in high-risk women who inherit a faulty BRCA1 gene.
BCAC member group Breast Cancer Cure has announced a new partnership with Cancer Research Trust to fund New Zealand research into breast cancer. Both organisations are philanthropic funders that have raised and granted millions of dollars to local cancer research over the last 25 years. The new funding will enable at least two new breast cancer research projects to be added to the work already being supported by Breast Cancer Cure.
Latest results from clinical trials with trastuzumab deruxtecan (brand name: Enhertu) have shown significant benefits for two groups of patients with advanced breast cancer: those with high levels of HER2 (HER2 positive), and also those with low levels of HER2 (HER2-low, a subset of HER2 negative breast cancers).
This drug has two components: trastuzumab allows it to home in on HER2 receptors on breast cancer cells, and then the deruxtecan component gets to work killing the cells.
Pharmac recently announced $190 million of new funding for medicines. However, only one breast cancer drug made it onto their investment list. Kadcyla (aka trastuzumab emtansine) is currently available in New Zealand only for those with advanced breast cancer.